About Michelle Bennett
Michelle specialises in mergers and acquisitions. She advises on a wide range of cross border public and private M&A transactions including share and asset sales, takeovers, schemes, demergers, joint ventures and corporate reorganisations. She also has a focus on corporate governance and head office matters.
In 2016, Michelle participated in a three month Jawun secondment to work with Aboriginal communities and organisations in the West Kimberley. On secondment, Michelle worked for Aarnja, an Aboriginal-controlled organisation which provides the backbone functions for the West Kimberley region as part of the Empowered Community reform with the Commonwealth Government.
Michelle's recent experience includes:
- Coles – advising on its demerger from Wesfarmers.
- Coles – advising on its FlyBuys joint venture with Wesfarmers.
- ANZ – advising on the sale of its pensions and investments and aligned dealer group business to IOOF, and its life and consumer credit businesses to Zurich.
- Consortium of bidders for Asciano Limited – advising on the consortium comprising GIP, CPPIB, CIC, GIC and BCIMC on the acquisition of Asciano Limited by scheme of arrangement.
- M2 Group – advising on the merger with ASX-listed Vocus Communications Ltd by scheme of arrangement.
- Vocus – advising on the acquisition of the telecommunications infrastructure assets of Nextgen.
- Bulletproof – advising on the takeover defence and Takeover Panel proceedings with Macquarie Telecom and the scheme of arrangement with AC3.
- Healthscope – advising on the divestment of its Asian pathology business to TPG.
- Goldman Sachs – advising the underwriter and sole lead manager of Chevron's block trade sale of its 50% interest in Caltex Australia Limited for $4.7billion.
- John Laing – advising on its acquisition of the 57.6MW Cherry Tree Wind Farm project from Infigen.
- Energy Developments Limited – advising on its acquisition of the 30MW Cullerin Range Wind Farm from Origin Energy Limited.
- GlaxoSmithKline – advising on the sale of its opiates business to Sun Pharmaceutical Industries (Australia), a subsidiary of India's largest pharmaceutical business.